Myelodysplastic syndromes - azacitidine: notice of appeal
Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia
The Institute has received four appeals against the Final Appraisal Determination and Guidance on this technology. The Institute has arranged the hearing for the appeals received against the FAD for the above technology. The appeal panel will convene on 1st June 2010 to hear oral representations from the appellants.
Members of the public, including consultees and commentators for this appraisal, and the press, may request to attend the hearing. The number of places for observers is constrained by the venue, and priority will be given to members of the public who are not employed by the appellant. There are twenty places available for this appeal hearing.
Where possible, requests to attend should be made using the form that will be available on the Institute’s web site. This form will be available from 22nd April 2010 only. The web site registration will allow requests to attend to be granted on a first-come, first-served basis. The registration period for this appeal will end at 5pm 10th May 2010. Further details relating to public attendance at this appeal are available on the same webpage as above.
A limited number of places at the appeal hearing will be reserved for members of the public who do not have access to the internet. These places should be applied for in writing, addressed to the Appeals Coordinator, to arrive before 5pm on 10th May 2010. Written requests to attend will also be granted on a first-come, first-served basis.
The name of the appellants will be published on the Institute’s web site on the day of the appeal. The Institute will not comment on speculation as to the identity of appellants prior to publication of this information on the Institute’s website.
This page was last updated: 13 April 2010